MedImmune names Tony Zook president
This article was originally published in Scrip
MedImmune, the wholly owned biologics business for AstraZeneca, has appointed Tony Zookpresident; he was heading the operation on an interim basis following the departure of David Mott in July. In addition to MedImmune, Mr Zook will be responsible forAstraZeneca's US and Canadian businesses, as well as the company's global marketing organisation. Mr Mott left MedImmune one year after the sale of the business to AstraZeneca for $15.6 billion. Earlier this month he joined Shire's board of directors as a non-executive director.